Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/19/2024 | $75.00 | Buy | H.C. Wainwright |
| 1/6/2023 | $2.00 → $3.00 | Neutral → Overweight | Piper Sandler |
| 1/6/2023 | $2.50 → $3.00 | Hold → Buy | Jefferies |
| 3/23/2022 | $15.00 → $4.00 | Overweight → Neutral | Piper Sandler |
| 3/11/2022 | $47.00 → $15.00 | Overweight | Piper Sandler |
| 3/11/2022 | $10.00 → $11.00 | Outperform | SVB Leerink |
| 2/16/2022 | $15.00 → $10.00 | Outperform | SVB Leerink |
| 1/7/2022 | $30.00 → $12.00 | Overweight → Neutral | JP Morgan |
8-K - Aligos Therapeutics, Inc. (0001799448) (Filer)
SCHEDULE 13G - Aligos Therapeutics, Inc. (0001799448) (Subject)
SCHEDULE 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
SOUTH SAN FRANCISCO, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company")), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 2,100 shares of the Company's stock (the "Inducement Grant") to newly hired employees on July 8, 2025 (the "Grant Date"), in connection with the commencement of employment. The Inducement Grants were granted pursuant to Aligos' 2024 Inducement Plan (the "Plan") as an inducement m
SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), effective immediately. "I am pleased to welcome Kieron to Aligos," said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. "With decades of experience, Kieron's extensive knowledge and broad expertise will undoubtedly provide invaluable leadership and oversight on all CMC-related matters."
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company")), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 26,000 shares of the Company's stock (the "Inducement Grant") to newly hired employees on June 10, 2025 (the "Grant Date"), in connection with the commencement of employment. The Inducement Grants were granted pursuant to Aligos' 2024 Inducement Plan (the "Plan") as an inducement
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls (CMC), effective immediately. "I am pleased to welcome Kieron to Aligos," said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. "With decades of experience, Kieron's extensive knowledge and broad expertise will undoubtedly provide invaluable leadership and oversight on all CMC-related matters."
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately. "I am thrilled to welcome Laura to the Aligos team," said Lesley Ann Calhoun, Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Aligos. "Laura brings with her a wealth of experience in all legal aspects from both biotech companies as well as large pharmaceutical firms. Her extensive knowledge and broad expe
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately. "We are pleased to welcome David to the Aligos team during this exciting time for the company," said Lesley Ann Calhoun, Executive Vice President and Chief Financial Officer at Aligos. "David's expertise in leading valuable partnerships will be instrumental as we strategically look to maximize the potential of our best-in-class pipeline
ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFFPlacebo-adjusted median relative reductions in liver fat were up to 46.2% with a clear dose responseALG-055009 was well-tolerated with no serious adverse events or dose reductions. Importantly, ALG-055009 dose groups had a similar incidence of gastrointestinal-related adverse events with less diarrhea compared to placeboSignificant reductions in atherogenic lipids, including LDL-C, lipoprotein (a), and apolipoprotein B were observedConference call scheduled for 8:30am ET/5:30am PT today SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alig
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company"))), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on Thursday, September 19, 2024 prior to the market open. Following the announcement, the Company will host a conference call and webcast at 8:30am ET/5:30am PT. Conference Call & Webcast Details Th
CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1bASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1st cohort fully enrolledsiRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studiesTHR-β (ALG-055009) currently dosing in healthy volunteers and subjects with hyperlipidemiaMultiple COVID-19 3CL protease inhibitor drug candidates without need for ritonavir boosting identified – all more potent than nirmatrelvirMerck expanded the NASH research collaboration utilizing Aligos' proprietary oligonucleotide technology Cash, cash equivalents and investments of $205.8 million as of December 31, 2021 A sufficient
SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
H.C. Wainwright initiated coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $75.00
Piper Sandler upgraded Aligos Therapeutics from Neutral to Overweight and set a new price target of $3.00 from $2.00 previously
Jefferies upgraded Aligos Therapeutics from Hold to Buy and set a new price target of $3.00 from $2.50 previously